Viatris expects to obtain the first US Food and Drug Administration approvals for interchangeable biosimilar products later this year, including the already available Semglee (insulin glargine) and the company’s pending biosimilar to NovoLog/NovoRapid (insulin aspart).
“Our 351k [biologics license application application] for insulin glargine for interchangeability is on track for a July FDA goal date,”...